The disclosure provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder, which includes nicotine, alcohol and/or cannabis dependence. The methods comprise determining a nucleic acid methylation profile from a biological sample from the subject for diagnosing that the subject has a predisposition to a substance use disorder.
COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO A SUBSTANCE USE DISORDER